A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of …
Diabetic nephropathy, also known as diabetic kidney disease (DKD), remains a challenge in
clinical practice as this is the major cause of kidney failure worldwide. Clinical trials do not …
clinical practice as this is the major cause of kidney failure worldwide. Clinical trials do not …
[HTML][HTML] Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
IH Vieira, TS Carvalho, J Saraiva, L Gomes, I Paiva - Biomedicines, 2024 - mdpi.com
Type 2 diabetes mellitus (T2DM) is a significant risk factor for stroke. Nevertheless, the
evidence supporting stringent glycemic control to reduce macrovascular complications …
evidence supporting stringent glycemic control to reduce macrovascular complications …
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk
T Nyström - Diabetes, Obesity and Metabolism, 2024 - Wiley Online Library
Abstract Sodium‐glucose cotransporter 2 (SGLT2) inhibitors, originally designed to manage
blood sugar levels in individuals with type 2 diabetes (T2D), have emerged as a crucial …
blood sugar levels in individuals with type 2 diabetes (T2D), have emerged as a crucial …
Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes
PT Htoo, M NajafZadeh, H Tesfaye… - Diabetes …, 2024 - Am Diabetes Assoc
OBJECTIVE We compared health care resource utilization (HCRU) and costs for inpatient
and outpatient services and dispensed medications in older adults with type 2 diabetes …
and outpatient services and dispensed medications in older adults with type 2 diabetes …
Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes
MR Riester, AR Zullo, R Joshi… - Diabetes, Obesity …, 2024 - Wiley Online Library
Aim Studies examining the safety and effectiveness of sodium‐glucose cotransporter‐2
inhibitors (SGLT2is) versus glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among …
inhibitors (SGLT2is) versus glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among …
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
PT Htoo, H Tesfaye, S Schneeweiss, DJ Wexler… - Cardiovascular …, 2024 - Springer
Following publication of the original article [1], the authors noticed an error in the hazard
ratio (HR) for the hospitalization for heart failure (HHF) outcome in the abstract. The numbers …
ratio (HR) for the hospitalization for heart failure (HHF) outcome in the abstract. The numbers …
A Case of Emphysematous Cystitis in an Elderly Male Diabetic Patient with Benign Prostatic Hyperplasia treated with an SGLT2-inhibitor
D Doornbos, L Herman, A Suraci - The Scholarly Society of …, 2024 - ssajm-online.org
Emphysematous cystitis is a rare and complicated urinary tract infection associated with gas
formation in the bladder wall. This is commonly associated with poorly controlled diabetes …
formation in the bladder wall. This is commonly associated with poorly controlled diabetes …
[PDF][PDF] Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes
BH vor der HĻohe, PT Htoo - researchgate.net
Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2
Diabetes Page 1 Health Care Utilization and Costs Associated With Empagliflozin in Older …
Diabetes Page 1 Health Care Utilization and Costs Associated With Empagliflozin in Older …